SYRS Syros Pharmaceuticals, Inc.

18.04
+0.61  (4%)
Previous Close 17.43
Open 17.27
Price To book 5.82
Market Cap 472.29M
Shares 26,180,000
Volume 178,386
Short Ratio 7.36
Av. Daily Volume 37,527

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated September 2016. Preliminary data due fall of 2017.
SY-1425
Relapsed or refractory Acute myeloid leukemia (AML) and relapsed high-risk Myelodysplastic Syndrome (MDS) - cancer
Phase 1/2 trial to be initiated 1H 2017.
SY-1365
Acute leukemia - cancer

Latest News

  1. Syros Presents Data at EHA Supporting Potential of SY-1425, Its First-in-Class Selective RARα Agonist, in Genomically Defined AML and MDS Patients
  2. Syros Presents Discovery of Key Genes Controlling the Autoimmune Response in Lupus in Late-Breaking Oral Presentation at FOCIS Meeting
  3. ETFs with exposure to Syros Pharmaceuticals, Inc. : June 15, 2017
  4. Syros to Participate in JMP Securities Life Sciences Conference
  5. Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SYRS-US : June 13, 2017
  6. Syros Appoints Srinivas Akkaraju to Its Board of Directors
  7. Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SYRS-US : May 29, 2017
  8. Syros to Present on SY-1425 in Combination with Standard-of-Care and Targeted Therapies in Genomically Defined Subsets of AML and MDS Patients
  9. Syros Reports First Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones
  10. Syros Announces First Patient Dosed in Phase 1 Clinical Trial of SY-1365, Its First-in-Class Selective CDK7 Inhibitor, in Patients with Advanced Solid Tumors
  11. Syros Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SYRS) : May 11, 2017
  12. Syros Announces Late-Breaking Oral Presentation on its Research Identifying Key Genes that Control the Auto-immune Response in Lupus at FOCIS Meeting
  13. Syros Presents New Insights on Mechanism of Action of SY-1425, Its First-in-Class Selective RARα Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference
  14. Syros Reveals Discovery of Novel Drug Targets for Triple Negative Breast Cancer
  15. Syros Participates in International Symposium to Support MDS Foundation’s Efforts to Raise Awareness of Novel Therapies in Development for MDS
  16. Syros to Present on Its Pioneering Approach to Identify Novel Drug Targets Linked to Genomically Defined Subsets of Patients at IMPAKT Breast Cancer Conference
  17. Syros Closes $35 Million Private Financing
  18. Syros Announces $35 Million Private Placement
  19. Syros to Present on SY-1425, Its First-in-Class Selective RARα Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference